Company intelligence / Profile preview
Azelon Pharmaceuticals
West Conshohocken/Conshohocken, Pennsylvania, United Statesbloomberg.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Phase 2
01
Overview
Azelon Pharmaceuticals developed ZT-034, a nasal spray formulation of teriparatide for osteoporosis treatment. The company conducted Phase 2 clinical trials to evaluate the effect of ZT-034 on bone formation compared to subcutaneous Forteo and placebo in postmenopausal women with low bone mass, as assessed by stimulation of serum P1NP levels[2][4].
- Therapeutic areas
- EndocrinologyRheumatology
- Modalities
- Parathyroid hormone analogsnasal spray formulations
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Azelon Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Azelon Pharmaceuticals.